
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc. is poised for a positive financial outlook driven by a significant increase in the average selling price (ASP) of its flagship product, Apligraf, which has risen fourfold, highlighting its competitive positioning within the advanced wound care market. While the company's performance has experienced variability due to market dynamics and forthcoming changes in reimbursement structures, recent results indicate a trend of improving unit volumes and solid operational performance during the latter part of 2026. Furthermore, an upward adjustment in the reimbursement rate for 2026 reflects favorable market conditions that may contribute to enhanced valuation and growth prospects for the company's regenerative medicine offerings.
Bears say
Organogenesis Holdings Inc. faces a negative outlook primarily due to anticipated challenges in the Advanced Wound Care market, with the company projecting a significant ~50% year-over-year decline in first-quarter 2026 revenues linked to product sizing waste and excess inventory. The risk factors include lower-than-expected growth in the PuraPly product line, unfavorable pricing changes for Medicare Part B on amniotic products, and increasing competitive pressures that may inhibit market share gains. Additionally, uncertainty surrounding the uptake of new products and the potential for adverse clinical data outcomes further contribute to the pessimistic financial forecast for the company.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares